2QFY27 Earnings Webinar

Sunshine Holdings PLC

02 November 2026

Housekeeping Announcements

- The webinar will be recorded and later uploaded to our IR website as well as CSE website for future reference (https://www.sunshineholdings.lk/investor-relations/)
- All participants will be muted during the presentation
- Participants can use the 'Raise Hand' option to ask questions during the Q&A session, and we will unmute them accordingly
- Participants can also raise their questions via the Q&A function

Agenda

01 **Corporate Announcements**

02 **Group Performance**

03 **Healthcare**

04 **Consumer**

05 **Agribusiness**

06 **Q&A**

07 **Appendix**

Team

SUNSHINE HOLDINGS



Shyam Sathasivam
Group CEO



Aruna Deepthikumara
Group CFO

SUNSHINE HEALTHCARE



Shantha Bandara
CEO – Sunshine Pharmaceuticals and Healthguard Distribution



Dr. Thiru Sayandhan
CEO – Sunshine Medical Devices and Lina Manufacturing



Farman Nizar
COO – Healthguard Pharmacy



Eranga Illangasinghe
Sector Financial Controller – Healthcare

SUNSHINE CONSUMER



Anuruddha Aluvihare
CEO – Sunshine Consumer Brands



Sanjeeva Saranapala
CEO – Sunshine Exports



Shafras Anver
Sector Financial Controller – Consumer

WATAWALA PLANTATIONS



Lasantha Perera
Sector Financial Controller – Plantations

Corporate Announcements

- 13th October 2026 – Zydus Sunshine Lifesciences, our 50:50 joint venture with India's Zydus Lifesciences, signed an agreement with the BOI to develop a GMP-compliant oral solid dosage manufacturing facility at the Horana Export Processing Zone.
- 16th October 2026 – Sunshine Healthcare acquired a 21.92% stake in Digital Health, operator of the Doc990 digital health platform, for LKR 410.8 Mn. The stake was bought from Digital Holdings (Dialog Axiata) and Ceylon Hospitals PLC.
- Sunshine Holdings stake in Watawala Plantations PLC (WATA) increased to 77.02% through Sunshine Wilmar. WATA also acquired the remaining stake in Lonach Dairy, making it a wholly owned subsidiary.
- 30th October 2026 – SUN declared a first interim dividend of LKR 0.5 per share for FY27, XD date - 10 Nov 2026, Payment date - 30 Nov 2026
- 29th October 2026 – WATA declared a first interim dividend of LKR 0.8 per share for FY27, XD date - 09 Nov 2026, Payment date - 27 Nov 2026

Group Performance

Group at a glance – 2QFY27

Revenue Composition – 2QFY27



LKR 3.6bn +27.5% YoY **EBIT**	LKR 2.3bn +84.7% YoY **Earnings**	LKR 0.74 +80.3% YoY **EPS**
29.8% +7.0 pts YoY **Gearing**	17.9% +4.2 pts YoY **ROE**	LKR 10.38 -1.4% YoY **NBV**
LKR 56.7bn -11.4% YoY **Mkt Cap**	15.4x **PER**	1.7% - 2QFY27 6.1% - FY26 **Div Yield**

Footnote : 1- Share price details as of 30th Sep 2026, **LKR 28.80**

Group – Performance Highlights

	2QFY27	2QFY26*	YoY%	1QFY27	QoQ %
Revenue	21,646	16,396	32.0%	18,538	16.8%
EBIT	3,628	2,846	27.5%	2,440	48.7%
EBIT margin	*16.8%*	*17.4%*		*13.2%*	
PAT	2,331	1,262	84.7%	1,407	65.6%
PAT margin	*10.8%*	*7.7%*		*7.6%*	
PATMI	1,451	805	80.3%	665	118.0%
EPS (LKR)	0.74	0.41	80.3%	0.34	118.0%

- Group revenue grew by 32.0% YoY to LKR 21.6 bn in 2QFY27. GP improved by 19.8% YoY to LKR 6.3 bn, however gross margin declined to 29.1% cf. 32.1% in 2QFY26.
- EBIT grew by 27.5% YoY to LKR 3.6 bn, while EBIT margin moderated to 16.8% in 2QFY27 cf. 17.4% recorded in 2QFY26.
- A lower effective tax rate and higher finance income resulted in a 307 bps improvement in PAT margin to 10.8%.

*Group PAT had been adjusted for WHT on subsidiary dividends for 2QFY26

Movement in Revenue & EBIT

Revenue Movement [LKR Million]



EBIT Movement [LKR Million]



Revenue Composition – Revenue QoQ



Healthcare

Sunshine Healthcare Lanka is Sri Lanka's only fully integrated healthcare company encompassing the entire pharma value chain

sunshine healthcare

2QFY27

10.5 bn
Revenue

13.5 %
EBIT Margin

9.1 %
PAT Margin

Manufacturing and R&D

Sri Lanka's first facility for Respiratory Care Research and Manufacturing, producing Respiratory Care Products and an Inhaler Device

Government and Local market

Capsules | Tablets | Nasal Spray | Devices | Creams | MDI

Contract manufacturing

KALBE

Importation and Agency

Sri Lanka's third largest (10.04% market share) importer in the Pharma and Medical Devices segment with access to 75+ principals

Key principals

CADILA PHARMACEUTICALS LIMITED | Zydus Cadila | novo nordisk | Glenmark | Abbott | SIEMENS | Erba Mannheim | 3M | Johnson & Johnson | GE Healthcare

Retail (Pharmacy)

Healthguard Pharmacy, has grown to 17 outlets in the Colombo district, becoming Sri Lanka's leading Health and Wellness chain

- Complete pharma offering
- Skilled, Educated, Qualified, Pharmacists
- Range & depth in wellness
- Digital centric organizational model

Distribution

Fully-fledged distribution division to assist local pharmaceutical importers and manufacturers in expanding their reach among retail pharmacy outlets across Sri Lanka

- Seven distribution centers with 25,000 sqft storage and 24x7 cold chain management
- Reaches 3,500 outlets in 620 towns, with scalable operations and fleet.

Revenue Split 2QFY27



Total Asset Split 2QFY27



Footnote : 1- Included under Importation and Agency

Healthcare Sector – Highlights

Sector Highlights

Sector revenue grew 20.5% YoY in 2QFY27, driven by strong growth in the medical devices, pharmaceutical manufacturing and distribution businesses.

Sector EBIT margin improved to 13.5% in 2QFY27, although price reductions in the pharmaceutical business continued to weigh on gross margins.

Outlook – With pricing pressure is expected to continue, our focus remains on product availability and growing our distribution, devices and manufacturing businesses.



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	1.7%	1.1%	12.8%	12.0%	32.6%	6.1%	5.9%	-11.8%	20.5%	15.0%
EBIT Margin (%)	12.2%		9.9%		11.8%		8.7%		13.5%	
PAT	210		653		1,143		732		954	
PAT Margin (%)	2.4%		6.7%		11.0%		8.0%		9.1%	
ROIC (%)	21.5%		17.3%		25.6%		21.8%		24.2%	

LKR Million unless stated otherwise

Sunshine Pharmaceuticals – Performance Highlights

Business Highlights

The pharmaceutical segment's revenue declined by 27.4% YoY in 2QFY27, mainly due to the high base in 2QFY26 following a one-off change in the business model, coupled with price reductions and supply-side challenges.

During the 12 months to June 2026, the market had value growth of 7.0% YoY (IQVIA MAT Jun 2026)



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	64.8%	72.8%	17.3%	-46.7%	-18.5%	-20.5%	-18.2%	11.8%	-27.4%	53.4%
RD Volume Growth (%) (YoY)	7.6%		2.2%		11.6%		-5.3%		-1.1%	
Market Share (%) – IQVIA MAT % - 3 months lag	10.2%		10.1%		10.1%		10.1%		10.0%	

LKR Million unless stated otherwise

Market Dynamics Hyperlink



Healthguard Distribution – Performance Highlights

Business Highlights

The Distribution segment's revenue grew by 8.5% YoY in 2QFY27, driven by a volume growth of 8.9%.

Growth was supported by higher volumes from key principals, despite stock-outs arising from regulatory constraints on import licence renewals.



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	17.4%	0.4%	16.4%	1.3%	26.5%	9.7%	-0.3%	-10.6%	8.5%	9.3%

LKR Million unless stated otherwise,

* Approximately 75% of the revenue is generated from internal customers in 2QFY27, which are classified as intercompany sales

Sunshine Medical Devices – Performance Highlights

Business Highlights

The Medical Devices segment recorded a 31.2% YoY revenue growth in 2QFY27, reflecting strong performance in both private and government segments during the quarter.



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	6.9%	-1.1%	1.1%	17.5%	27.3%	0.8%	8.8%	-7.1%	31.2%	19.3%

LKR Million unless stated otherwise

Market Dynamics Hyperlink



Lina Manufacturing – Performance Highlights

Business Highlights

During 2QFY27, revenue from the manufacturing business recorded a robust growth of 49.3% YoY, primarily driven by government product deliveries in line with the calendar year 2026 requirements. MDI capacity utilisation improved to 89% during the quarter.



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	-15.0%	2.7%	-19.5%	26.2%	105.1%	-23.8%	20.5%	22.1%	49.3%	27.2%
MDI Capacity Utilization (%)*	90%		76%		22%		76%		89%	

LKR Million unless stated otherwise

*MDI Capacity Utilization reflect packed quantities

Healthguard Pharmacy – Performance Highlights

Business Highlights

The Retail segment, Healthguard Pharmacy, recorded a flat revenue performance with a 0.1% YoY growth in 2QFY27, as price increase was offset by volume decline, mainly in the wellness range.



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	12.9%	2.2%	9.9%	1.4%	5.9%	-0.8%	-0.9%	-3.6%	0.1%	3.3%
Same store sales (SSS) growth (%)*	9.0%		6.0%		2.2%		-2.4%		-1.0%	
Bill count growth (SS) (%)	6.6%		7.3%		-1.1%		-6.7%		0.6%	
Average Basket Value growth (SS) (%)	2.2%		3.0%		6.1%		4.5%		-0.6%	
Availability (Top Pharma SKUs) (%)	88%		93%		95%		94%		93%	

LKR Million unless stated otherwise

Consumer Sector

Sunshine Consumer, market leader in branded tea, confectionery and organic Ceylon cinnamon exports

sunshine consumer

sunshine consumer

2QFY27

8.4 bn
Revenue

9.9 %
EBIT Margin

5.4 %
PAT Margin

Tea

Largest branded tea company in Sri Lanka – 49.0% General Trade market share. *Pepper Cube Sep 2026, Shares are 3 months average for end period

Catering to three distinct need and value segments, the portfolio comprising of three brands: Zesta, Watawala Thei and Ran Kahata

Confectionery

Market leader in the hard-boiled candies category

Brands consist of Daintee, Milady, X-tra and Daintee Hearts

Tea Exports

Exports value-added-tea products, including procuring, blending, packaging, and contract manufacturing of tea for private labels

Exports to 40+ countries, including USA, China, UAE and Germany

Spice Exports

Sri Lanka's leading organic cinnamon exporter by shipment value, with a broad spice and coconut portfolio

Exports to 20+ countries, including Germany, Netherlands, Italy and the USA

Brand Portfolio

Revenue Split 2QFY27



Total Asset Split 2QFY27



Consumer Sector – Highlights

Sector Highlights

Consumer sector revenue grew 68.4% YoY to LKR 8.4 Bn in 2QFY27, covering our tea and confectionery brands and tea and spice exports..

Growth was mainly driven by the consolidation of JAPC, our cinnamon export business. Excluding JAPC, revenue grew 23.4% YoY, led by tea exports.

Outlook: Export growth is expected to continue, supported by new business, while we keep investing behind our tea and confectionery brands.



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	-1.5%	4.2%	2.3%	-5.0%	3.8%	-4.0%	38.0%	45.2%	68.4%	27.2%
EBIT Margin (%)	9.6%		6.3%		4.9%		5.6%		9.9%	
PAT	278		166		78		249		456	
PAT Margin (%)	5.6%		3.5%		1.7%		3.8%		5.4%	
ROIC (%)	13.3%		15.5%		12.4%		10.6%		12.1%	

LKR Million unless stated otherwise

*4QFY26 - Includes Daintee goodwill impairment

*1QFY27 & 2QFY27 include JAPC; FY2025/26 JAPC comparative quarterly figures are estimated at one-fourth of the audited annual financial statements.

Tea Brands – Performance Highlights

Business Highlights

Revenue from the Branded Tea business grew by 3.4% YoY to LKR 2.7 Bn in 2QFY27, supported by growth in the general trade channel.

Watawala Thei remained the key volume contributor, while Ran Kahata recorded the strongest revenue growth during the quarter. Zesta volumes declined YoY due to continued competitive pressure in the premium segment and softer demand in modern trade.



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	8.3%	15.6%	11.1%	3.6%	8.9%	-2.8%	8.3%	-7.0%	3.4%	10.4%
Volume (kgs '000)	1,352		1,396		1,361		1,243		1,326	
Volume Growth % (YoY) | (QoQ)	10.4%	16.5%	11.9%	3.2%	10.6%	-2.6%	7.1%	-8.7%	-2.0%	6.7%
Market Share (%) – Quarter Average	48.5%		47.2%		48.2%		49.4%		49.0%	

LKR Million unless stated otherwise

Market Dynamics Hyperlink



Confectionery Brands – Performance Highlights

Business Highlights

Revenue from the Confectionery business declined by 2.2% YoY in 2QFY27, mainly due to lower sales in the Toffee/Candy category, partly offset by strong growth in the Gums and Wafers categories.



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	-5.5%	5.3%	17.9%	-14.6%	7.2%	11.3%	6.9%	6.7%	-2.2%	-3.7%
Volume (kgs '000)	492		434		469		486		465	
Volume Growth % (YoY) | (QoQ)	-6.1%	6.3%	23.6%	-11.8%	4.4%	8.0%	5.0%	3.6%	-5.5%	-4.3%
Market Share (%) – Quarter Average	14.6%		13.3%		14.0%		14.8%		14.1%	

LKR Million unless stated otherwise

Market Dynamics Hyperlink



Tea Exports – Performance Highlights

Business Highlights

The export business recorded a revenue growth of 60.8% YoY in 2QFY27 to reach LKR 3.0 Bn, mainly driven by incremental business from existing customers and higher sales of value-added products.



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	-9.2%	-10.5%	-12.1%	-12.0%	-5.2%	-10.8%	-6.3%	33.4%	60.8%	53.7%
Volume (kgs '000)*	948		801		713		922		1,248	
Volume Growth % (YoY) | (QoQ)	12.7%	-11.2%	-7.4%	-15.5%	9.0%	-11.0%	-13.6%	29.3%	31.6%	35.4%

LKR Million unless stated otherwise

*Volume includes only exported quantities and excludes local contract packing volumes

Spice Exports – Performance Highlights

Business Highlights

The spice export business recorded a revenue growth of 45.7% YoY in 2QFY27 to reach LKR 2.2 Bn, mainly driven by improved pricing and a favourable product mix.

Sales volume improved by 11.0% YoY driven by higher spice orders, supported by a strong order book.



Investor Metrics	1QFY27		2QFY27	
Revenue Growth % (YoY)* | (QoQ)	11.5%	11.5%	45.7%	30.7%
Volume (kgs '000)*	761		707	
Volume Growth % (YoY)* | (QoQ)	19.5%	19.5%	11.0%	-7.0%

LKR Million unless stated otherwise

*FY2025/26 JAPC's comparative quarterly figures are estimated based on one-fourth of the audited annual financial statements.

Agribusiness

Watawala Plantations PLC primarily engages in palm oil and dairy farming

Watawala Plantations PLC

2QFY27

2.8 bn
Revenue

48.5 %
EBIT Margin

31.5 %
PAT Margin

Palm Oil

A land extent of ~3,400 Ha under palm oil cultivation

The first in South Asia to receive RSPO certification for sustainable oil palm plantation

Positioning – largest oil palm cultivator in Sri Lanka

Dairy

661 milking cows / 1,611 herd

Board of Investment (BOI) registered project which commercial operations in Aug 2017

DAIRYMASTER milking parlour system capable of monitoring the progress of each animal's yield and quality of milk produced

Revenue Split 2QFY27



Total Asset Split 2QFY27



Agribusiness – Highlights

Sector Highlights

The Agribusiness sector reported revenue of LKR 2.8 Bn in 2QFY27, reflecting a 2.1% YoY improvement, driven by the performance of the palm oil business.

The dairy business also showed an improvement, with its losses narrowing compared to the corresponding period last year

Outlook: We expect palm oil demand to remain favourable. Our focus will be on productivity, cost discipline and sustainable practices, alongside further improvements in the dairy business.



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	23.0%	8.3%	17.6%	-23.0%	13.3%	4.7%	12.7%	29.2%	2.1%	-2.0%
EBIT Margin (%)	49.3%		36.9%		20.0%		47.2%		48.5%	
PAT / PAT Margin (%)	899	33.3%	459	22.1%	146	6.7%	885	31.5%	867	31.5%
ROIC (%)	41.8%		41.9%		44.2%		50.5%		42.4%	

LKR Million unless stated otherwise

Palm Oil – Performance Highlights

Business Highlights

The Palm Oil segment recorded 4.8% YoY improvement in revenue in 2QFY27, driven by favourable pricing, which offset lower sales volumes due to reduced bought crop availability and lower oil extraction rates.



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	23.1%	8.2%	30.9%	-17.9%	16.8%	6.4%	17.9%	32.1%	4.8%	-3.9%
EBIT Margin (%)	59.2%		43.2%		28.4%		54.2%		55.5%	
PAT / PAT Margin (%)	967	41.3%	535*	27.8%	555*	28.7%	949	37.2%	902	36.8%
Sales Volume [CPO & KPO] (MT)	4,613		3,478		4,043		4,831		4,524	

* - Excluding Impairment of Goodwill on acquisition of subsidiary

LKR Million unless stated otherwise

Dairy – Performance Highlights

Business Highlights

The dairy business recorded a 0.8% YoY growth in revenue in 2QFY27, supported by a higher average milk selling price despite lower milk sales volumes.

The EBIT loss narrowed to LKR 26 Mn compared to LKR 40 Mn in 2QFY26, supported by improved gross profitability and higher other income



Investor Metrics	2QFY26		3QFY26		4QFY26		1QFY27		2QFY27	
Revenue Growth % (YoY) | (QoQ)	2.9%	7.5%	-11.6%	-11.6%	-8.5%	-7.5%	-7.1%	5.8%	0.8%	16.6%
EBIT Margin (%)	-13.4%		-23.8%		-36.3%		-21.8%		-8.5%	
PAT / PAT Margin (%)	-52	-17.4%	-75	-28.2%	-42	-17.2%	-64	-24.9%	-35	-11.7%
Sales Volume ('000)	1,310		1,154		1,025		1,027		1,192	
Average Milk Price	229		229		239		252		253	

LKR Million unless stated otherwise

*2QFY26 - Adjusted for the fair value loss in Biological Assets of LKR 16m

*4QFY26 - Adjusted for the fair value loss in Biological Assets of LKR 361m

Q&A

Appendix

Investment in Digital Health (Doc990)

Transaction Overview

21.92%
Stake held in Digital Health

LKR 410.8 Mn
Total consideration

16 Oct 2026
Transaction completed

Seller	Stake	LKR Mn
Digital Holdings Lanka (Pvt) Ltd (subsidiary of Dialog Axiata PLC)	16.65%	312.2
Ceylon Hospitals PLC (tag-along rights)	5.26%	98.7
Total	**21.92%**	**410.8**

About Doc990

- Digital Health (Private) Limited operates Doc990, an integrated digital healthcare platform in Sri Lanka, launched in 2016
- Connects patients, doctors, hospitals and corporates through mobile app, web and call-based channels
- Services include doctor channelling, audio / video consultations, medicine delivery, lab reports, hospital and pharmacy management systems, and corporate health solutions

Strategic Rationale

- Extends the Healthcare sector into digital health, complementing our pharmaceutical, distribution, manufacturing and retail businesses
- A minority investment that gives the Group exposure to the growing digital health segment and supports the continued growth of the Doc990 platform
- Positioned to benefit from rising demand for convenient, digitally enabled access to healthcare in Sri Lanka

Source – CSE disclosure dated 16th October 2026, Company Information

Key ratios – 2QFY27

INVESTOR RATIOS

	2QFY27	2QFY26
EPS TTM	LKR 1.87	LKR 1.42
ROE	17.88%	13.65%
PER TTM	15.41	22.84
NAV	10.38	10.53
PBV	2.77	3.09

PROFITABILITY RATIOS

	2QFY27	2QFY26
GP Margin	29.1%	32.1%
EBIT Margin	16.8%	17.4%
PAT Margin	10.8%	7.7%

Footnote : 1- Share price details as of 30th Sep 2026, **LKR 28.80**

Sunshine Pharmaceuticals – Market Dynamics

During 2Q IQVIA, the market experienced a growth of 7.0% (2Q 2026 MAT YoY %)



Source – IQVIA, Management Information

SHP – Sunshine Pharmaceuticals

IQVIA data are based on calendar year periods and are reported with a three-month lag

Sunshine Medical Devices – Market Dynamics



Source – Management Information

Brand Value Market Share (%) – Tea



Source: Peppercube RMS

Brand Value Market Share (%) – Confectionary



Source: Peppercube RMS

Price Index – Tea and Confectionary



Jan 2025 considered as the base (i.e., 100)

Source – Management Information



4QFY24 considered as the base (i.e., 100)

Source – Management Information

Agribusiness – Price Movement

Settlement Price (RM)



Source - Malaysian contract price

WDL's Avg Milk Price (LKR)



Source – Management Information

Forward Looking Statements

This presentation contains forward-looking statements that are based on management's current expectations and assumptions. Forward-looking statements include predictions of future results or activities and may contain the words "expects," "believes," "should," "will," "anticipates," "projects," "estimates," "implies," "can," or words or phrases of similar meaning. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Our predictions could be affected by a variety of factors, including: competitive dynamics and the markets for our products, including new product introductions, advertising activities, pricing actions and promotional activities of our competitors; economic conditions, including changes in inflation rates, interest rates, tax rates, or the availability of capital; product development and innovation; consumer acceptance of new products and product improvements; consumer reaction to pricing actions and changes in promotion levels; acquisitions or dispositions of businesses or assets; changes in capital structure; changes in laws and regulations, including labeling and advertising regulations; impairments in the carrying value of intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets; changes in accounting standards and the impact of significant accounting estimates; product quality and safety issues, including recalls and product liability; changes in consumer demand for our products; effectiveness of advertising, marketing and promotional programs; changes in consumer behavior, trends and preferences, including weight loss trends; consumer perception of health-related issues; consolidation in the retail environment; changes in purchasing and inventory levels of significant customers; fluctuations in the cost and availability of supply chain resources, including raw materials, packaging and energy; disruptions or inefficiencies in the supply chain; benefit plan expenses due to changes in plan asset values and discount rates used to determine plan liabilities; failure or breach of our information technology systems; foreign economic conditions, including currency rate fluctuations; and political unrest in foreign markets and economic uncertainty due to terrorism or war.

The company undertakes no obligation to publicly revise any forward-looking statements to reflect any future events or circumstances.

Thank you!

For more information, Please visit our Investor Relations page

https://www.sunshineholdings.lk/investor-relations/